Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%

Zomedica Corp. (NYSEAMERICAN:ZOM) shares traded down 4.3% during mid-day trading on Friday . The company traded as low as $0.12 and last traded at $0.12. 6,579,362 shares traded hands during trading, an increase of 25% from the average session volume of 5,268,323 shares. The stock had previously closed at $0.13.

Zomedica Stock Performance

The stock has a market capitalization of $121.22 million, a PE ratio of -3.09 and a beta of 1.00.

Zomedica (NYSEAMERICAN:ZOM) last issued its quarterly earnings data on Monday, April 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Zomedica had a negative net margin of 137.10% and a negative return on equity of 8.13%. The firm had revenue of $7.34 million during the quarter, compared to analyst estimates of $7.00 million.

Institutional Trading of Zomedica

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Zomedica by 5.1% during the third quarter. Vanguard Group Inc. now owns 46,329,005 shares of the company’s stock worth $9,775,000 after buying an additional 2,252,651 shares in the last quarter. BlackRock Inc. grew its position in shares of Zomedica by 5.6% during the first quarter. BlackRock Inc. now owns 13,418,299 shares of the company’s stock worth $4,523,000 after buying an additional 707,993 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Zomedica by 4.3% during the first quarter. Geode Capital Management LLC now owns 9,302,960 shares of the company’s stock worth $1,969,000 after buying an additional 386,149 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Zomedica during the second quarter worth approximately $552,000. Finally, Swiss National Bank grew its position in shares of Zomedica by 7.6% during the first quarter. Swiss National Bank now owns 2,201,200 shares of the company’s stock worth $742,000 after buying an additional 156,100 shares in the last quarter. Institutional investors and hedge funds own 8.95% of the company’s stock.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.